ライフサイエンスコーパス: interferon alfa-2b

1 acarbazine, IL-2 9 MU/m(2)/d for 4 days, and interferon alfa-2b).

2 he adverse effects were similar to those for interferon alfa-2b.

3 apy consisting of CVD plus interleukin-2 and interferon alfa-2b.

4 atment and after follow-up, as compared with interferon alfa-2b.

5 only complicates treatment with the cytokine interferon alfa-2b.

6 who are candidates for adjuvant therapy with interferon alfa-2b.

7 nfection were treated with standard doses of interferon alfa-2b.

8 nt with oral cimetidine (15% vs 5%), topical interferon alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), p

9 Treatment consisted of interferon alfa-2b 10 x 10(6) U subcutaneously three tim

10 45 patients received initial treatment with interferon alfa-2b (16 of whom crossed over to DA-EPOCH-

11 (15.2-77.5) after cross-over treatment with interferon alfa-2b, 25.4% (8.2-47.2) after initial treat

12 odeficiency virus were randomized to receive interferon alfa-2b (3 million units 3 times a week) plus

13 two doses of CIFN (3 microg and 9 microg) or interferon alfa-2b (3 million units [MU]) weekly for 24

14 through 5 and as a bolus on days 12 and 19), interferon alfa-2b (3 million units subcutaneously three

15 ng either consensus interferon (9 microg) or interferon alfa-2b (3 million units) given three times w

16 ients treated with CIFN (9 microg) than with interferon alfa-2b (3 MU).

17 yotherapy with adjuvant topical or injection interferon alfa-2b (38% vs 15%).

18 % CI 33.2-62.1) after initial treatment with interferon alfa-2b, 50.0% (15.2-77.5) after cross-over t

19 sis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly syn

20 mes a week) plus ribavirin (1,000 mg/day) or interferon alfa-2b alone for 48 weeks with 24 weeks of p

21 oic acid may offer a superior alternative to interferon alfa-2b alone in treating CIN.

22 chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribaviri

23 ed in 3 published clinical trials evaluating interferon alfa-2b alone or with ribavirin either as ini

24 pared the efficacy and safety of recombinant interferon alfa-2b alone with those of a combination of

25 umor-free period compared with studies using interferon alfa-2b alone.

26 s C (n = 103) were treated for 24 weeks with interferon alfa 2b and followed up for 24 weeks after ce

27 25%) of 51 patients receiving treatment with interferon alfa-2b and 21 (64%) of 33 patients receiving

28 bazine or this same chemotherapy followed by interferon alfa-2b and interleukin-2.

29 l of 1,744 patients with HCV received either interferon alfa-2b and placebo or combination interferon

30 We believe that combination treatment of interferon alfa-2b and retinoic acid may offer a superio

31 white nonresponders (NR) to a combination of interferon alfa-2b and ribavirin (IFN + R).

32 rly virologic response [EVR]) with pegylated interferon alfa-2b and ribavirin (PEG/R) in identifying

33 nterferon alfa-2b and placebo or combination interferon alfa-2b and ribavirin for 24 or 48 weeks.

34 alfa-2b alone with those of a combination of interferon alfa-2b and ribavirin for the initial treatme

35 he efficacy, safety, and pharmacokinetics of interferon alfa-2b and ribavirin in children with chroni

36 For chronic hepatitis C, the combination of interferon alfa-2b and ribavirin is the treatment of cho

37 Multiple-dose interferon alfa-2b and ribavirin peak and trough concent

38 e, and both a new ropegylated formulation of interferon alfa-2b and ruxolitinib have been approved in

39 ated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple rec

40 ll-known antiangiogenic agents (minocycline, interferon alfa-2b, and fumagillin) and were stored for

41 ction, and one haemophagocytic syndrome with interferon alfa-2b, and one infection and one haemophago

42 erapy, oral cimetidine, topical or injection interferon alfa-2b, and photodynamic therapy.

43 e, vinblastine, cisplatin, decrescendo IL-2, interferon alfa-2b, and tamoxifen was repeated at 21-day

44 evoflurane, the combination of ribavirin and interferon alfa-2b, and various betamethasone-containing

45 r alone or concurrent with interleukin-2 and interferon alfa-2b (BCT).

46 NA positive after 6 months of treatment with interferon alfa-2b but had a histological response.

47 (on days 5 to 8, 17 to 20, and 26 to 29) and interferon alfa-2b by subcutaneous injection (on days 5

48 atitis B, treatment with a 4-month course of interferon alfa-2b can achieve hepatitis B e antigen ser

49 t recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and

50 Monotherapy with standard or pegylated interferon alfa-2b; combination therapy with standard or

51 ssigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to

52 either the standard three-times-weekly (TIW) interferon alfa-2b dose (3 MIU) or the once-weekly (QW)

53 in the mean serum HCV RNA concentration than interferon alfa-2b during treatment (P < .01).

54 mination prior to a single 6-month course of interferon alfa-2b; empirical interferon treatment; and

55 nts receiving a combination of ribavirin and interferon alfa-2b experienced an increased incidence of

56 day) or RBV (800-1400 mg/day) with pegylated interferon alfa-2b for 48 weeks.

57 Patients received interferon alfa-2b for a minimum of 4 weeks, followed by

58 ompared peginterferon alfa-2b (PegIntron) to interferon alfa-2b for the initial treatment of compensa

59 he efficacy, safety, and timing of pegylated interferon alfa-2b for treatment of acute hepatitis C.

60 th DA-EPOCH-R (eight of whom crossed over to interferon alfa-2b); four underwent surveillance only.

61 e rates to 3, 5, or 10 million units (MU) of interferon alfa-2b, given thrice weekly, and to determin

62 Treatment with interferon alfa-2b has been limited by its cost and low

63 therapeutic agents such as interleukin-2 and interferon alfa-2b has been reported to provide improved

64 High-dose interferon alfa-2b (HDI) has emerged as a potentially ef

65 High-dose interferon alfa-2b (HDI) was administered concurrently,

66 Adjuvant high-dose interferon-alfa-2b (HDI) improves disease-free and overa

67 Adjuvant therapy with interferon alfa-2b holds promise for patients with metas

68 Interferon alfa-2b (IFN alpha-2b) exhibits antitumor act

69 Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma

70 cted with HIV and HCV to receive 48 weeks of interferon alfa-2b (IFN) 3 million units three times wee

71 /m2, 5-FU 640 mg/m2/d as a 120-hour CIV, and interferon alfa-2b (IFN) at 2 MU/m2/d for 6 days for thr

72 Interferon alfa-2b (IFN) in a randomized clinical trial

73 for hepatitis C, we assessed the efficacy of interferon alfa-2b (IFN) in preventing recurrent hepatit

74 value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2

75 As second-line therapy, he received interferon alfa-2b (IFN--2b) 2.7 MU daily, which he tole

76 C melanoma were randomly assigned to receive interferon alfa-2b (IFN-alpha-2b) 20 MIU/m(2) intravenou

77 ession-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide am

78 Interleukin-12 (IL-12) and interferon alfa-2b (IFN-alpha-2b) are pleiotropic cytoki

79 tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-li

80 estigated maintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose oste

81 d active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved u

82 pe 1 virus (HCV) is dependent on the dose of interferon alfa-2b (IFN-alpha2b), the acute clearance of

83 eron, with a standard regimen of recombinant interferon alfa-2b (IFN-alpha2b).

84 reliminary efficacy of once-weekly pegylated interferon alfa-2b (IFNalpha-2b) in patients with advanc

85 High-dose interferon alfa-2b (IFNalpha2b) is the only established

86 Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk mel

87 In conclusion, interferon alfa-2b in combination with ribavirin is effe

88 all available randomized clinical trials of interferon alfa-2b in patients with chronic hepatitis C.

89 en subsequently used it, in combination with interferon alfa-2b, in a second cohort of this study and

90 polypeptide of recombinant human albumin and interferon alfa-2b, in patients with chronic hepatitis C

91 orse adverse events in patients treated with interferon alfa-2b included neutropenia (27 [53%] of 51

92 Interferon alfa-2b is efficacious for treating low-grade

93 after chemotherapy, for which treatment with interferon alfa-2b is efficacious.

94 ize that topical all-trans retinoic acid and interferon alfa-2b may act synergistically.

95 is an immunocytokine comprising 2 attenuated interferon alfa-2b molecules and an anti-CD38 immunoglob

96 conditions were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK

97 radical nephrectomy followed by therapy with interferon alfa-2b or to receive interferon alfa-2b ther

98 er inflammation to a greater extent than did interferon alfa-2b, particularly in subjects with sustai

99 Adjuvant pegylated interferon alfa-2b (PEG-IFN-alpha-2b) was approved for t

100 nts treated with variable-duration pegylated interferon alfa-2b (PEG-IFN-alpha2b) and RBV.

101 riple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which

102 on of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 per

103 Children receiving interferon alfa-2b plus ribavirin 15 mg/kg/d in the phas

104 a-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significa

105 stained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-

106 Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a

107 ety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alf

108 terferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin.

109 hout adjuvant oral cimetidine and/or topical interferon alfa-2b provide satisfactory tumor control.

110 I trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched wit

111 Recombinant interferon alfa-2b (rIFNalpha2b) is a standard therapy f

112 th low-grade disease received dose-escalated interferon alfa-2b, starting at 7.5 million internationa

113 se, whereas, after cross-over treatment with interferon alfa-2b, the overall response was 63% (five o

114 After initial treatment with interferon alfa-2b, the overall response was 64% (28 of

115 mized trial evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph nod

116 Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard a

117 herapy with interferon alfa-2b or to receive interferon alfa-2b therapy alone.

118 In comparison with no treatment, interferon alfa-2b therapy was associated with significa

119 apsed or were nonresponders to prior CIFN or interferon alfa-2b therapy.

120 toxicity associated with adjuvant high-dose interferon-alfa-2b therapy (HDI) for high-risk melanoma

121 herapy with at least 2 million units (MU) of interferon alfa-2b three times weekly for 24 weeks.

122 itis C virus (HCV) were treated with 5 MU of interferon alfa-2b three times weekly for 6 months.

123 were randomized to receive 3, 5, or 10 MU of interferon alfa-2b thrice weekly for 12 weeks.

124 2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin fo

125 Interferon alfa-2b-treated patients also had significant

126 rogressive pulmonary metastasis resistant to interferon alfa-2b treatment 7 months after he underwent

127 ery from melphalan, patients were to receive interferon alfa-2b until relapse.

128 in patients treated with CIFN (9 microg) and interferon alfa-2b was 7% and 0%, respectively (P = .03)

129 ation treatment of topical retinoic acid and interferon alfa-2b was effective in treating lesions wit

130 Responses to 3 MU interferon alfa-2b were comparable to 9 microg CIFN.

131 y for 24 weeks, and lower doses of pegylated interferon alfa-2b were less effective than standard dos

132 1.0, 1.5 microg/kg) the clinical efficacy of interferon alfa-2b while preserving its safety profile.

133 azine, decrescendo interleukin-2 (IL-2), and interferon alfa-2b with granulocyte-macrophage colony-st